CClinicalTrials.gg
Sign In
RecruitingNCT05437692Updated Oct 12, 2022

Zimberelimab Combined With Concurrent Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer

A Phase 2 interventional study of zimberelimab combined With concurrent radiotherapy and chemotherapy in Locally Advanced Cervical Cancer, sponsored by Shanghai Zhongshan Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-10-12.

Sponsored by Shanghai Zhongshan Hospital · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Started Jul 2022; still recruiting 4 years 2 months later.
Phase
Phase 2
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Study summary

This is a prospective, single arm, phase II clinical study on the treatment of locally advanced cervical cancer (Ⅱ B to Ⅳ a) with Zimberelimab combined with concurrent radiotherapy and chemotherapy.

Read the detailed description

This study will include 19 patients with locally advanced cervical cancer to explore the efficacy and safety of Zimberelimab in combination with concurrent radiotherapy for them.

02

Conditions studied

  • Locally Advanced Cervical Cancer
03

In context

Uterine Cervical Neoplasms

1,879 studies on the registry are indexed under Uterine Cervical Neoplasms; 565 are open to participants now.

This study's planned enrollment of 19 is below the median of 100 across 1,375 interventional studies indexed under Uterine Cervical Neoplasms.

Browse Uterine Cervical Neoplasms studies →

Lead sponsor

Shanghai Zhongshan Hospital is the lead sponsor of 636 studies on the registry; 283 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • FIGO 2018 stage IIB to IVA cervical cancer;
  • Cervical squamous cell carcinoma, cervical adenocarcinoma or cervical adenosquamous carcinoma confirmed by histology;
  • Have not received any radiotherapy for cervical cancer in the past, and have not received immunotherapy;
  • Have measurable lesions (according to RECIST v1.1 standard);
  • ECOG score: 0 \~ 1;
  • 18\~75 years old (calculated on the day of signing the informed consent);
  • The estimated survival period exceeds 6 months;
  • Before enrollment, try to provide enough tumor tissue samples (archived or fresh biopsy samples) to evaluate and confirm the expression of PD-L1 and to detect other biomarkers; Considering the accessibility of clinical specimens, there is no mandatory requirement for specimens;
  • Women of childbearing age should agree to use contraceptives (such as intrauterine devices, contraceptives or condoms) during the study period and within ● months after the end of the study; Within 7 days before the study was enrolled, the serum or urine pregnancy test was negative, and must be non lactating patients;
  • For the full organ function defined in the protocol, the test samples must be collected within 7 days before the start of the study treatment;
  • The patients volunteered to join the study and signed the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • The subjects have other histological subtypes except those permitted by inclusion criteria 2;
  • Bilateral hydronephrosis, unless at least one side has been implanted with a stent or solved by a positioned nephrostomy;
  • Those who are allergic to gadolinium, a common non-ionic CT contrast agent and a magnetic resonance contrast agent
  • Have anatomical structure or tumor geometry or any other reasons or contraindications that cannot be treated with intracavitary brachytherapy or intracavitary and implantable brachytherapy;
  • Severe hypersensitivity (≥ grade 3) to cepalimumab and / or any of its excipients;
  • Participated in or had participated in clinical trials within 4 weeks before randomization;
  • Have been vaccinated or will be vaccinated with live vaccine within 30 days before the first study treatment;
  • Have received systemic immune stimulant, colony stimulating factor, interferon, interleukin and vaccine combination treatment within 6 weeks or 5 half lives (whichever is shorter) before the first administration;
  • Within 7 days before the first administration, the patient has been diagnosed with immune deficiency or is receiving chronic systemic steroid therapy (the dose exceeds 10mg prednisone equivalent per day) or any other form of immunosuppressive therapy;
  • Active autoimmune diseases requiring systemic treatment during the past two years (such as the use of disease regulating drugs, corticosteroids or immunosuppressive drugs);
  • Have a history of (non infectious) pneumonia requiring steroid treatment or currently have (non infectious) pneumonia;
  • Active infection requiring systematic treatment;
  • Known HIV infection history;
  • Known hepatitis B (defined as HBsAg reactivity) or known active hepatitis C virus (defined as detection of HCV RNA [qualitative]) infection history;
  • Known history of active tuberculosis (TB; Mycobacterium tuberculosis);
  • Received allogeneic tissue / solid organ transplantation;
  • Central nervous system metastasis such as tumor brain metastasis;
  • Patients with uncontrolled hydrothorax and ascites;
  • Patients with movement disorders such as pathological fractures caused by tumor bone metastasis;
  • Insufficient hematopoietic function of bone marrow (without blood transfusion within 14 days):
  • Abnormal liver:
  • Abnormal kidney:
  • Risk of bleeding:
  • Cardiovascular and cerebrovascular abnormalities:
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (estimated)

Study arms

  • Experimental
    zimberelimab plus concurrent radiotherapy and chemotherapy

    19 patients will treated with zimberelimab plus concurrent radiotherapy and chemotherapy

    Drug: zimberelimab combined With concurrent radiotherapy and chemotherapy

Interventions

  • Drugzimberelimab combined With concurrent radiotherapy and chemotherapy

    zimberelimab: 240 mg Q2W Intravenous drip，The maximum duration of medication shall not exceed one years; chemotherapy: Starting from the first week of radiotherapy and chemotherapy, cisplatin 40mg/m2 and paclitaxel 35mg/m2 were given intravenously for 30-60min; Radiotherapy: intensity modulated radiation therapy (IMRT) was used for external irradiation. The total dose of pelvic cavity and lymph drainage planning target area (PTV) was 45-50 gy/25-28f. The metastatic lymph nodes should be able to supplement or synchronously push 10-15 Gy; The internal irradiation was started within 2 weeks after the end of external irradiation treatment. The image-guided three-dimensional brachytherapy was used, and 30-40gy was added to make the total dose of point a reach 80-85 Gy, twice a week, 5-6gy each time. All radiotherapy was completed within 8 weeks.

    Also known as: GSL-010

06

What researchers measure

Primary outcomes

  1. ORR

    Objective response rate based on RECIST v1.1

    Time frame: one year

Secondary outcomes

  1. adverse events

    adverse events evaluation based on NCI-CTCAE 5.0

    Time frame: two years

  2. DCR

    Disease control rate evaluation based on RECIST v1.1

    Time frame: one year

  3. OS

    overall survival time

    Time frame: three years

  4. PFS

    Progression free survival time

    Time frame: two years

07

Study locations

1 of 1 sites recruiting
  • Shanghai Zhongshan hospital
    Shanghai, Shanghai 200032, China
    • Clinical trial institution Office of Zhongshan Hospital, MD · Contact · sun.wei5@zs-hospital.sh.cn · 021-31587861
    • Lin Genlai, MD · Principal investigator
    Recruiting
08

References and documents

Publications

  • Wright JD, Matsuo K, Huang Y, Tergas AI, Hou JY, Khoury-Collado F, St Clair CM, Ananth CV, Neugut AI, Hershman DL. Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines. Obstet Gynecol. 2019 Jul;134(1):49-57. doi: 10.1097/AOG.0000000000003311. PubMed 31188324 ↗
  • Arbyn M, Weiderpass E, Bruni L, de Sanjose S, Saraiya M, Ferlay J, Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020 Feb;8(2):e191-e203. doi: 10.1016/S2214-109X(19)30482-6. Epub 2019 Dec 4. Erratum In: Lancet Glob Health. 2022 Jan;10(1):e41. doi: 10.1016/S2214-109X(21)00554-4. PubMed 31812369 ↗
  • Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Clark R, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Wyse E, Yashar CM, McMillian NR, Scavone JL. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 Jan;17(1):64-84. doi: 10.6004/jnccn.2019.0001. PubMed 30659131 ↗
  • Kokka F, Bryant A, Brockbank E, Powell M, Oram D. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer. Cochrane Database Syst Rev. 2015 Apr 7;(4):CD010260. doi: 10.1002/14651858.CD010260.pub2. PubMed 25847525 ↗
  • Pakish JB, Jazaeri AA. Immunotherapy in Gynecologic Cancers: Are We There Yet? Curr Treat Options Oncol. 2017 Aug 24;18(10):59. doi: 10.1007/s11864-017-0504-y. PubMed 28840453 ↗
  • Mandal R, Chan TA. Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy. Cancer Discov. 2016 Jul;6(7):703-13. doi: 10.1158/2159-8290.CD-16-0146. Epub 2016 Apr 22. PubMed 27107038 ↗
  • Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, Chen HZ, Reeser JW, Yu L, Roychowdhury S. Landscape of Microsatellite Instability Across 39 Cancer Types. JCO Precis Oncol. 2017;2017:PO.17.00073. doi: 10.1200/PO.17.00073. Epub 2017 Oct 3. PubMed 29850653 ↗
  • Shao C, Li G, Huang L, Pruitt S, Castellanos E, Frampton G, Carson KR, Snow T, Singal G, Fabrizio D, Alexander BM, Jin F, Zhou W. Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors. JAMA Netw Open. 2020 Oct 1;3(10):e2025109. doi: 10.1001/jamanetworkopen.2020.25109. PubMed 33119110 ↗
  • Liu Y, Wu L, Tong R, Yang F, Yin L, Li M, You L, Xue J, Lu Y. PD-1/PD-L1 Inhibitors in Cervical Cancer. Front Pharmacol. 2019 Feb 1;10:65. doi: 10.3389/fphar.2019.00065. eCollection 2019. PubMed 30774597 ↗
  • Frenel JS, Le Tourneau C, O'Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C, van Brummelen EMJ, Rugo HS, Thomas S, Saraf S, Rangwala R, Varga A. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. J Clin Oncol. 2017 Dec 20;35(36):4035-4041. doi: 10.1200/JCO.2017.74.5471. Epub 2017 Nov 2. PubMed 29095678 ↗
  • Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, Manzuk L, Piha-Paul SA, Xu L, Zeigenfuss S, Pruitt SK, Leary A. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2019 Jun 10;37(17):1470-1478. doi: 10.1200/JCO.18.01265. Epub 2019 Apr 3. PubMed 30943124 ↗
  • Tamura K, Hasegawa K, Katsumata N, Matsumoto K, Mukai H, Takahashi S, Nomura H, Minami H. Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial. Cancer Sci. 2019 Sep;110(9):2894-2904. doi: 10.1111/cas.14148. Epub 2019 Sep 3. PubMed 31348579 ↗
  • Naumann RW, Hollebecque A, Meyer T, Devlin MJ, Oaknin A, Kerger J, Lopez-Picazo JM, Machiels JP, Delord JP, Evans TRJ, Boni V, Calvo E, Topalian SL, Chen T, Soumaoro I, Li B, Gu J, Zwirtes R, Moore KN. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial. J Clin Oncol. 2019 Nov 1;37(31):2825-2834. doi: 10.1200/JCO.19.00739. Epub 2019 Sep 5. PubMed 31487218 ↗
  • Santin AD, Deng W, Frumovitz M, Buza N, Bellone S, Huh W, Khleif S, Lankes HA, Ratner ES, O'Cearbhaill RE, Jazaeri AA, Birrer M. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecol Oncol. 2020 Apr;157(1):161-166. doi: 10.1016/j.ygyno.2019.12.034. Epub 2020 Jan 7. PubMed 31924334 ↗
  • Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, Tewari KS, Salman P, Hoyos Usta E, Yanez E, Gumus M, Olivera Hurtado de Mendoza M, Samouelian V, Castonguay V, Arkhipov A, Toker S, Li K, Keefe SM, Monk BJ; KEYNOTE-826 Investigators. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med. 2021 Nov 11;385(20):1856-1867. doi: 10.1056/NEJMoa2112435. Epub 2021 Sep 18. PubMed 34534429 ↗
  • Menderes G, Black J, Schwab CL, Santin AD. Immunotherapy and targeted therapy for cervical cancer: an update. Expert Rev Anticancer Ther. 2016;16(1):83-98. doi: 10.1586/14737140.2016.1121108. Epub 2015 Dec 7. PubMed 26568261 ↗
  • Wang CC, Chou HH, Yang LY, Lin H, Liou WS, Tseng CW, Liu FY, Liou JD, Huang KG, Huang HJ, Huang EY, Chen CH, Chang TC, Chang CJ, Hong JH, Lai CH. A randomized trial comparing concurrent chemoradiotherapy with single-agent cisplatin versus cisplatin plus gemcitabine in patients with advanced cervical cancer: An Asian Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jun;137(3):462-7. doi: 10.1016/j.ygyno.2015.03.046. Epub 2015 Mar 28. PubMed 25827291 ↗
  • Thakur P, Seam R, Gupta M, Gupta M. Prospective randomized study comparing concomitant chemoradiotherapy using weekly cisplatin & paclitaxel versus weekly cisplatin in locally advanced carcinoma cervix. Ann Transl Med. 2016 Feb;4(3):48. doi: 10.3978/j.issn.2305-5839.2015.11.19. PubMed 26904570 ↗

Study documents

  • Informed consent form · May 5, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No — IPD will not be shared.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05437692
Lead sponsor
Shanghai Zhongshan Hospital
Responsible party
Sponsor
First posted
Jun 29, 2022
Start date
Jul 15, 2022
Primary completion
Jul 1, 2024 (estimated)
Completion
Jul 1, 2025 (estimated)
Last update
Oct 12, 2022

Study contacts

Lin Genlai, MD
Contact
lin.genlai@zs-hospital.sh.cn
13816034376
Lin Genlai, MD
principal investigator · Shanghai Zhongshan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Uterine Cervical Neoplasms→

Other studies from this sponsor

Shanghai Zhongshan Hospital

Start the discussion